ELSEVIER LICENSE
TERMS AND CONDITIONS
Sep 25, 2020
This Agreement between INRS -- Ahlem Zaghmi ("You") and Elsevier ("Elsevier") consists
of your license details and the terms and conditions provided by Elsevier and Copyright
Clearance Center.
License Number
4915920975548
License date
Sep 25, 2020
Licensed Content
Publisher
Elsevier
Licensed Content
Publication
Neuron
Licensed Content Title
Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology
and Its Impact on Clinical Treatments
Licensed Content Author Paul M. George,Gary K. Steinberg
Licensed Content Date
Jul 15, 2015
Licensed Content Volume 87
Licensed Content Issue
2
Licensed Content Pages
13
Start Page
297
End Page
309
9/25/2020 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 2/7
Portion
figures/tables/illustrations
Number of
figures/tables/illustrations
1
Format
both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating?
No
Title
PhD student
Institution name
INRS-EMT Canada
Expected presentation date Dec 2020
Portions
Figure 1
Requestor Location
INRS
1650 Lionel-Boulet
Varennes, QC J3X 1S2
Canada
Attn: INRS
Publisher Tax ID
GB 494 6272 12
Total
0.00 CAD
Terms and Conditions
INTRODUCTION
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection
with completing this licensing transaction, you agree that the following terms and conditions
apply to this transaction (along with the Billing and Payment terms and conditions
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your
Rightslink account and that are available at any time at
http://myaccount.copyright.com
).
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source. If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier’s permissions helpdesk
here
). No modifications can be made to
any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is finally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted. Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
9/25/2020 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 4/7
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions. These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction. In the event of
any conflict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you. Notice of such denial will be made using the contact information provided by you.
Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx
or the Elsevier homepage for books at
http://www.elsevier.com
; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at
http://www.elsevier.com
. All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona fide students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been
peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes
author-incorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the definitive final
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
9/25/2020 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 6/7
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a
CrossMark logo
, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's
posting policy
for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is defined by the author's choice of Creative
Commons user license. See our
open access license policy
for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at
http://creativecommons.org/licenses/by/4.0
.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at
http://creativecommons.org/licenses/by-nc-sa/4.0
.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at
http://creativecommons.org/licenses/by-nc-nd/4.0
.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.10
Questions?
customercare@copyright.com
or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
Transforming Discoveries into Therapies
ASPET · 1801 Rockville Pike, Suite 210 · Rockville, MD 20852 · Office: 301-634-7060 · aspet.org
Council
Charles P. France President
University of Texas Health Science Center
Margaret E. Gnegy President-Elect
University of Michigan Medical School
Wayne L. Backes Past President
Louisiana State University Health Sciences Center
Mary-Ann Bjornsti Secretary/Treasurer
University of Alabama, Birmingham Carol L. Beck
Secretary/Treasurer-Elect Thomas Jefferson University Jin Zhang
Past Secretary/Treasurer University of California, San Diego Kathryn A. Cunningham Councilor
University of Texas Medical Branch
Namandjé N. Bumpus Councilor
Johns Hopkins University School of Medicine
Randy A. Hall Councilor
Emory University School of Medicine
Emily E. Scott
Chair, Board of Publications Trustees
University of Michigan Catherine M. Davis FASEB Board Representative Johns Hopkins University School of Medicine
Michael W. Wood Chair, Program Committee Neupharm LLC
Judith A. Siuciak Executive Officer
September 29, 2020 Ahlem Zaghmi
Institut National de la Recherche Scientifique EMT Research Center
Université de Québec Varennes, QC
Canada
Email: ahlem.zaghmi@emt.inrs.ca Dear Ahlem Zaghmi:
This is to grant you permission to include the following figures in your thesis titled “Development of multi-PEGylated enzymes: activity loss mechanisms and application for ischemic stroke treatment” for the INRS “Énergie, Matériaux et Télécommunications:
Figures 2 and 3 from M Demeule, A Régina, C Ché, J Poirier, T Nguyen, R Gabathuler, J-P Castaigne, and R Béliveau (2009) Identification and Design of Peptides as a New Drug Delivery System for the Brain, J
Pharmacol Exp Ther, 324(3): 1064-1072; DOI:
https://doi.org/10.1124/jpet.107.131318
Permission to reproduce the figures is granted for worldwide use in all languages, translations, and editions, and in any format or medium including print and electronic. The authors and the source of the materials must be cited in full, including the article title, journal title, volume, year, and page numbers.
Sincerely yours,
Richard Dodenhoff Journals Director
0123423131 56789 6 ÿ6 9ÿÿ6 9
./0.12
.3ÿ
536.3ÿ
6.782
/0
59:
ÿ
;;<
ÿ
;=;=
7>?
@ÿ
8AB
CCDCE:
ÿ
FC:
GCCEÿ
8>H
CDÿ
IJA>D?
ÿ
K
LMNOLP
ÿ
JEQÿ
.H
@CR?
CB
ÿ
K
L.H
@CR?
CB
LP
ÿ
9NE@?
@:
@ÿ
NS
ÿ
TNOB
NB
QCB
ÿ
QC:
J?
H
@ÿ
JEQÿ
:
>Cÿ
:
CB
D@ÿ
JEQÿ
9NEQ?
:
?
NE@ÿ
UB
NR?
QCQÿ
FTÿ
.H
@CR?
CB
ÿ
JEQÿ
VNUTB
?
A>:
ÿ
VH
CJB
JE9C
VCE:
CB
W
5B
QCB
ÿ
XODFCB
Y=Z[=\]=Z
5B
QCB
ÿ
QJ:
C
59:
ÿ
;Z<
ÿ
;=;=
/?
9CE@CQÿ
VNE:
CE:
ÿ
^OFH
?
@>CB
.H
@CR?
CB
/?
9CE@CQÿ
VNE:
CE:
ÿ
^OFH
?
9J:
?
NE
.H
@CR?
CB
ÿ
_NN`@
/?
9CE@CQÿ
VNE:
CE:
ÿ
7?
:
H
C
VNEb
^NH
TDCB
OAJ:
a
C@
^B
N:
C?
E
/?
9CE@CQÿ
VNE:
CE:
ÿ
8O:
>NB
8>H
CD
IJA>D?
<
8EQB
CJÿ
8W
cB
C@9>ECB
<
dJB
9ÿ
8W
cJO:
>?
CB
/?
9CE@CQÿ
VNE:
CE:
ÿ
6J:
C
;=;=
/?
9CE@CQÿ
VNE:
CE:
ÿ
^JAC@
Z]
0:
JB
:
ÿ
^JAC
e]f
.EQÿ
^JAC
g=[
7TUCÿ
NS
ÿ
h@C
:
B
>C@?
CO@Cÿ
@i
?
Q?
Eÿ
@@CB
J
:
J:
?
NE
2
ÿ
JDÿ
JEÿ
J9JQCD?
9ÿ
NB
ÿ
ANRCB
EDCE:
ÿ
?
E@:
?
:
O:
?
NEÿ
G?
:
>ÿ
Jÿ
S
OH
H
a
:
Cj:
@OF@9B
?
U:
?
NEÿ
:
Nÿ
:
>?
@ÿ
b
NOB
EJH
ÿ
JEQÿ
:
>Cÿ
JOQ?
CE9Cÿ
NS
ÿ
:
>Cÿ
DJ:
CB
?
JH
ÿ
9NE@?
@:
@
NS
ÿ
@:
OQCE:
@ÿ
JEQi
NB
ÿ
CDUH
NTCC@ÿ
NS
ÿ
:
>?
@ÿ
?
E@:
?
:
O:
Ck
XN
^NB
:
?
NE
S
OH
H
ÿ
9>JU:
CB
V?
B
9OH
J:
?
NE
;===
lNB
DJ:
FN:
CH
C9:
>ÿ
B
UB
NE?
?
E:
9
ÿ
JEQ
8B
Cÿ
TNOÿ
:
>Cÿ
JO:
>NB
ÿ
NS
ÿ
:
>?
@ÿ
.H
@CR?
CB
ÿ
9>JU:
CB
k
MC@
m?
H
H
ÿ
TNOÿ
FCÿ
:
B
JE@H
J:
?
EAk
XN
7?
:
H
C
^>6ÿ
@:
OQCE:
2
E@:
?
:
O:
?
NEÿ
EJDC
2
X30a
.d7ÿ
VJEJQJ
.jUC9:
CQÿ
UB
C@CE:
J:
?
NEÿ
QJ:
C
6C9ÿ
;=;=
5B
QCB
ÿ
B
CS
CB
CE9Cÿ
EODFCB
X8
3CnOC@:
NB
ÿ
/N9J:
?
NE
2
X30
Z[Y=ÿ
/?
NECH
a
_NOH
C:
1JB
CEEC@<
ÿ
oVÿ
peq
Z0;
VJEJQJ
8:
:
Er
ÿ
2
X30
^OFH
?
@>CB
ÿ
7Jjÿ
2
6
c_ÿ
gfgÿ
[;\;ÿ
Z;
_?
H
H
?
EAÿ
7TUC
2
ERN?
9C
0123423131 56789 6 ÿ6 9ÿÿ6 9 89922011 6789 2 9 ! 6 26 9"!#$% & ! 6 '!()&*10+1,-10 32,
./01ÿ
34
5678
9
:5;8
7<
=>?
7667@A
ÿ
BCÿ
DEF
.GH
C>6>I>
J<
<
6K
ÿ
JL8
7Mÿ
N>OLM4
P5<
>8
1Q
11ÿ
CJR
P7?
M@ÿ
>6Iÿ
C56I4
<
4
56@
STUVWXYZUSWT
.Q
ÿ
PL7ÿ
[;\8
4
@L7?
ÿ
]
5?
ÿ
<
L4
@ÿ
^5[_?
4
OL<
7Iÿ
M><
7?
4
>8
ÿ
4
@ÿ
`8
@7a4
7?
Q
ÿ
ÿ
:_ÿ
^8
4
^b4
6Oÿ
c>^^7[<
cÿ
4
6ÿ
^5667^<
4
56
d4
<
Lÿ
^5M[8
7<
4
6Oÿ
<
L4
@ÿ
8
4
^76@4
6Oÿ
<
?
>6@>^<
4
56A
ÿ
_5;ÿ
>O?
77ÿ
<
L><
ÿ
<
L7ÿ
]
58
8
5d4
6Oÿ
<
7?
M@ÿ
>6Iÿ
^56I4
<
4
56@
>[[8
_ÿ
<
5ÿ
<
L4
@ÿ
<
?
>6@>^<
4
56ÿ
e
>8
56Oÿ
d4
<
Lÿ
<
L7ÿ
:4
8
8
4
6Oÿ
>6Iÿ
f>_M76<
ÿ
<
7?
M@ÿ
>6Iÿ
^56I4
<
4
56@
7@<
>\8
4
@L7Iÿ
\_ÿ
C5[_?
4
OL<
ÿ
C8
7>?
>6^7ÿ
C76<
7?
A
ÿ
g
6^Q
ÿ
e
cCCCch
A
ÿ
><
ÿ
<
L7ÿ
<
4
M7ÿ
<
L><
ÿ
_5;ÿ
5[767Iÿ
_5;?
i4
OL<
@8
4
6bÿ
>^^5;6<
ÿ
>6Iÿ
<
L><
ÿ
>?
7ÿ
>a>4
8
>\8
7ÿ
><
ÿ
>6_ÿ
<
4
M7ÿ
><
ÿ
L<
<
[K
j
j
M_>^^5;6<
Q
^5[_?
4
OL<
Q
^5M
h
Q
klTlVmnÿ
UlVpq
HQ
ÿ
`8
@7a4
7?
ÿ
L7?
7\_ÿ
O?
>6<
@ÿ
_5;ÿ
[7?
M4
@@4
56ÿ
<
5ÿ
?
7[?
5I;^7ÿ
<
L7ÿ
>]
5?
7M76<
4
567Iÿ
M><
7?
4
>8
ÿ
@;\r
7^<
ÿ
<
5
<
L7ÿ
<
7?
M@ÿ
>6Iÿ
^56I4
<
4
56@ÿ
4
6I4
^><
7IQ
EQ
ÿ
J^b65d8
7IO7M76<
K
ÿ
g
]
ÿ
>6_ÿ
[>?
<
ÿ
5]
ÿ
<
L7ÿ
M><
7?
4
>8
ÿ
<
5ÿ
\7ÿ
;@7Iÿ
e
]
5?
ÿ
7s>M[8
7A
ÿ
]
4
O;?
7@h
ÿ
L>@
>[[7>?
7Iÿ
4
6ÿ
5;?
ÿ
[;\8
4
^><
4
56ÿ
d4
<
Lÿ
^?
7I4
<
ÿ
5?
ÿ
>^b65d8
7IO7M76<
ÿ
<
5ÿ
>65<
L7?
ÿ
@5;?
^7A
ÿ
[7?
M4
@@4
56
M;@<
ÿ
>8
@5ÿ
\7ÿ
@5;OL<
ÿ
]
?
5Mÿ
<
L><
ÿ
@5;?
^7Q
ÿ
ÿ
g
]
ÿ
@;^Lÿ
[7?
M4
@@4
56ÿ
4
@ÿ
65<
ÿ
5\<
>4
67Iÿ
<
L76ÿ
<
L><
ÿ
M><
7?
4
>8
M>_ÿ
65<
ÿ
\7ÿ
4
6^8
;I7Iÿ
4
6ÿ
_5;?
ÿ
[;\8
4
^><
4
56j
^5[4
7@Q
ÿ
G;4
<
>\8
7ÿ
>^b65d8
7IO7M76<
ÿ
<
5ÿ
<
L7ÿ
@5;?
^7
M;@<
ÿ
\7ÿ
M>I7A
ÿ
74
<
L7?
ÿ
>@ÿ
>ÿ
]
55<
65<
7ÿ
5?
ÿ
4
6ÿ
>ÿ
?
7]
7?
76^7ÿ
8
4
@<
ÿ
><
ÿ
<
L7ÿ
76Iÿ
5]
ÿ
_5;?
ÿ
[;\8
4
^><
4
56A
ÿ
>@
]
58
8
5d@K
ci7[?
4
6<
7Iÿ
]
?
5Mÿ
f;\8
4
^><
4
56ÿ
<
4
<
8
7A
ÿ
=58
ÿ
j
7I4
<
4
56ÿ
6;M\7?
A
ÿ
J;<
L5?
e
@h
A
ÿ
P4
<
8
7ÿ
5]
ÿ
>?
<
4
^8
7ÿ
j
ÿ
<
4
<
8
7ÿ
5]
^L>[<
7?
A
ÿ
f>O7@ÿ
t5Q
A
ÿ
C5[_?
4
OL<
ÿ
e
u7>?
h
A
ÿ
d4
<
Lÿ
[7?
M4
@@4
56ÿ
]
?
5Mÿ
`8
@7a4
7?
ÿ
v
wiÿ
Jff3g
CJ:3`
GwCg
`Puÿ
Cwfuig
xyPÿ
wzt`i{
Q
cÿ
J8
@5ÿ
3>6^7<
ÿ
@[7^4
>8
ÿ
^?
7I4
<
ÿ
9
ÿ
ci7[?
4
6<
7Iÿ
]
?
5Mÿ
PL7
3>6^7<
A
ÿ
=58
Q
ÿ
6;M\7?
A
ÿ
J;<
L5?
e
@h
A
ÿ
P4
<
8
7ÿ
5]
ÿ
>?
<
4
^8
7A
ÿ
f>O7@ÿ
t5Q
A
ÿ
C5[_?
4
OL<
ÿ
e
u7>?
h
A
ÿ
d4
<
L
[7?
M4
@@4
56ÿ
]
?
5Mÿ
`8
@7a4
7?
Q
c
|Q
ÿ
i7[?
5I;^<
4
56ÿ
5]
ÿ
<
L4
@ÿ
M><
7?
4
>8
ÿ
4
@ÿ
^56]
4
67Iÿ
<
5ÿ
<
L7ÿ
[;?
[5@7ÿ
>6Ij
5?
ÿ
M7I4
>ÿ
]
5?
ÿ
dL4
^L
[7?
M4
@@4
56ÿ
4
@ÿ
L7?
7\_ÿ
O4
a76Q
0Q
ÿ
J8
<
7?
4
6Oj
}5I4
]
_4
6Oÿ
}><
7?
4
>8
K
ÿ
t5<
ÿ
f7?
M4
<
<
7IQ
ÿ
y5d7a7?
ÿ
]
4
O;?
7@ÿ
>6Iÿ
4
8
8
;@<
?
><
4
56@ÿ
M>_ÿ
\7
>8
<
7?
7Ij
>I>[<
7Iÿ
M4
64
M>8
8
_ÿ
<
5ÿ
@7?
a7ÿ
_5;?
ÿ
d5?
bQ
ÿ
J6_ÿ
5<
L7?
ÿ
>\\?
7a4
><
4
56@A
ÿ
>II4
<
4
56@A
ÿ
I78
7<
4
56@
>6Ij
5?
ÿ
>6_ÿ
5<
L7?
ÿ
>8
<
7?
><
4
56@ÿ
@L>8
8
ÿ
\7ÿ
M>I7ÿ
568
_ÿ
d4
<
Lÿ
[?
4
5?
ÿ
d?
4
<
<
76ÿ
>;<
L5?
4
~><
4
56ÿ
5]
ÿ
`8
@7a4
7?
3<
IQ
ÿ
e
f8
7>@7ÿ
^56<
>^<
ÿ
`8
@7a4
7?
@ÿ
[7?
M4
@@4
56@ÿ
L78
[I7@bÿ
L7?
7
h
Q
ÿ
t5ÿ
M5I4
]
4
^><
4
56@ÿ
^>6ÿ
\7ÿ
M>I7ÿ
<
5
>6_ÿ
3>6^7<
ÿ
]
4
O;?
7@j
<
>\8
7@ÿ
>6Iÿ
<
L7_ÿ
M;@<
ÿ
\7ÿ
?
7[?
5I;^7Iÿ
4
6ÿ
]
;8
8
Q
/Q
ÿ
g
]
ÿ
<
L7ÿ
[7?
M4
@@4
56ÿ
]
77ÿ
]
5?
ÿ
<
L7ÿ
?
7;7@<
7Iÿ
;@7ÿ
5]
ÿ
5;?
ÿ
M><
7?
4
>8
ÿ
4
@ÿ
d>4
a7Iÿ
4
6ÿ
<
L4
@ÿ
4
6@<
>6^7A
[8
7>@7ÿ
\7ÿ
>Ia4
@7Iÿ
<
L><
ÿ
_5;?
ÿ
]
;<
;?
7ÿ
?
7;7@<
@ÿ
]
5?
ÿ
`8
@7a4
7?
ÿ
M><
7?
4
>8
@ÿ
M>_ÿ
><
<
?
>^<
ÿ
>ÿ
]
77Q
Q
ÿ
i7@7?
a><
4
56ÿ
5]
ÿ
i4
OL<
@K
ÿ
f;\8
4
@L7?
ÿ
?
7@7?
a7@ÿ
>8
8
ÿ
?
4
OL<
@ÿ
65<
ÿ
@[7^4
]
4
^>8
8
_ÿ
O?
>6<
7Iÿ
4
6ÿ
<
L7
^5M\4
6><
4
56ÿ
5]
ÿ
e
4
h
ÿ
<
L7ÿ
8
4
^76@7ÿ
I7<
>4
8
@ÿ
[?
5a4
I7Iÿ
\_ÿ
_5;ÿ
>6Iÿ
>^^7[<
7Iÿ
4
6ÿ
<
L7ÿ
^5;?
@7ÿ
5]
ÿ
<
L4
@
8
4
^76@4
6Oÿ
<
?
>6@>^<
4
56A
ÿ
e
4
4
h
ÿ
<
L7@7ÿ
<
7?
M@ÿ
>6Iÿ
^56I4
<
4
56@ÿ
>6Iÿ
e
4
4
4
h
ÿ
CCC
@ÿ
:4
8
8
4
6Oÿ
>6Iÿ
f>_M76<
<
7?
M@ÿ
>6Iÿ
^56I4
<
4
56@Q
Q
ÿ
34
^76@7ÿ
C56<
4
6O76<
ÿ
[56ÿ
f>_M76<
K
ÿ
zL4
8
7ÿ
_5;ÿ
M>_ÿ
7s7?
^4
@7ÿ
<
L7ÿ
?
4
OL<
@ÿ
8
4
^76@7I
4
MM7I4
><
78
_ÿ
;[56ÿ
4
@@;>6^7ÿ
5]
ÿ
<
L7ÿ
8
4
^76@7ÿ
><
ÿ
<
L7ÿ
76Iÿ
5]
ÿ
<
L7ÿ
8
4
^76@4
6Oÿ
[?
5^7@@ÿ
]
5?
ÿ
<
L7
0123423131 56789 6 ÿ6 9ÿÿ6 9
.
/
01203.
4
516
ÿ
8/
594
:;:ÿ
.
<0.
ÿ
=5>ÿ
<09;ÿ
:4
23?
52;:ÿ
35@8?
;.
;ÿ
01:ÿ
033>/
0.
;ÿ
:;.
04
?
2ÿ
5A
ÿ
=5>/
ÿ
8/
5852;:
>2;6
ÿ
15ÿ
?
4
3;12;ÿ
4
2ÿ
A
4
10?
?
=ÿ
;A
A
;3.
4
9;ÿ
>1?
;22ÿ
01:ÿ
>1.
4
?
ÿ
A
>?
?
ÿ
80=@;1.
ÿ
4
2ÿ
/
;3;4
9;:ÿ
A
/
5@ÿ
=5>ÿ
B
;4
.
<;/
C=ÿ
8>C?
4
2<;/
ÿ
5/
ÿ
C=ÿ
DDDE
ÿ
02ÿ
8/
594
:;:ÿ
4
1ÿ
DDDF
2ÿ
G4
?
?
4
1Hÿ
01:ÿ
I0=@;1.
ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
512J
ÿ
ÿ
K
A
A
>?
?
ÿ
80=@;1.
ÿ
4
2ÿ
15.
ÿ
/
;3;4
9;:ÿ
51ÿ
0ÿ
.
4
@;?
=ÿ
C024
26
ÿ
.
<;1ÿ
01=ÿ
?
4
3;12;ÿ
8/
;?
4
@4
10/
4
?
=ÿ
H/
01.
;:ÿ
2<0?
?
ÿ
C;
:;;@;:ÿ
0>.
5@0.
4
30?
?
=ÿ
/
;95L;:ÿ
01:ÿ
2<0?
?
ÿ
C;ÿ
954
:ÿ
02ÿ
4
A
ÿ
1;9;/
ÿ
H/
01.
;:J
ÿ
ÿ
M>/
.
<;/
6
ÿ
4
1ÿ
.
<;ÿ
;9;1.
.
<0.
ÿ
=5>ÿ
C/
;03<ÿ
01=ÿ
5A
ÿ
.
<;2;ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
512ÿ
5/
ÿ
01=ÿ
5A
ÿ
DDDF
2ÿ
G4
?
?
4
1Hÿ
01:ÿ
I0=@;1.
.
;/
@2ÿ
01:ÿ
351:4
.
4
5126
ÿ
.
<;ÿ
?
4
3;12;ÿ
4
2ÿ
0>.
5@0.
4
30?
?
=ÿ
/
;95L;:ÿ
01:ÿ
2<0?
?
ÿ
C;ÿ
954
:ÿ
02ÿ
4
A
ÿ
1;9;/
H/
01.
;:J
ÿ
ÿ
N2;ÿ
5A
ÿ
@0.
;/
4
0?
2ÿ
02ÿ
:;23/
4
C;:ÿ
4
1ÿ
0ÿ
/
;95L;:ÿ
?
4
3;12;6
ÿ
02ÿ
O;?
?
ÿ
02ÿ
01=ÿ
>2;ÿ
5A
ÿ
.
<;
@0.
;/
4
0?
2ÿ
C;=51:ÿ
.
<;ÿ
2358;ÿ
5A
ÿ
01ÿ
>1/
;95L;:ÿ
?
4
3;12;6
ÿ
@0=ÿ
3512.
4
.
>.
;ÿ
358=/
4
H<.
ÿ
4
1A
/
4
1H;@;1.
01:ÿ
8>C?
4
2<;/
ÿ
/
;2;/
9;2ÿ
.
<;ÿ
/
4
H<.
ÿ
.
5ÿ
.
0L;ÿ
01=ÿ
01:ÿ
0?
?
ÿ
03.
4
51ÿ
.
5ÿ
8/
5.
;3.
ÿ
4
.
2ÿ
358=/
4
H<.
ÿ
4
1ÿ
.
<;
@0.
;/
4
0?
2J
PJ
ÿ
Q0/
/
01.
4
;2R
ÿ
I>C?
4
2<;/
ÿ
@0L;2ÿ
15ÿ
/
;8/
;2;1.
0.
4
512ÿ
5/
ÿ
O0/
/
01.
4
;2ÿ
O4
.
<ÿ
/
;28;3.
ÿ
.
5ÿ
.
<;ÿ
?
4
3;12;:
@0.
;/
4
0?
J
STJ
ÿ
K
1:;@14
.
=R
ÿ
U5>ÿ
<;/
;C=ÿ
4
1:;@14
A
=ÿ
01:ÿ
0H/
;;ÿ
.
5ÿ
<5?
:ÿ
<0/
@?
;22ÿ
8>C?
4
2<;/
ÿ
01:ÿ
DDD6
ÿ
01:
.
<;4
/
ÿ
/
;28;3.
4
9;ÿ
5A
A
4
3;/
26
ÿ
:4
/
;3.
5/
26
ÿ
;@8?
5=;;2ÿ
01:ÿ
0H;1.
26
ÿ
A
/
5@ÿ
01:ÿ
0H04
12.
ÿ
01=ÿ
01:ÿ
0?
?
3?
04
@2ÿ
0/
4
24
1Hÿ
5>.
ÿ
5A
ÿ
=5>/
ÿ
>2;ÿ
5A
ÿ
.
<;ÿ
?
4
3;12;:ÿ
@0.
;/
4
0?
ÿ
5.
<;/
ÿ
.
<01ÿ
02ÿ
28;34
A
4
30?
?
=ÿ
0>.
<5/
4
V;:
8>/
2>01.
ÿ
.
5ÿ
.
<4
2ÿ
?
4
3;12;J
SSJ
ÿ
W5ÿ
X/
012A
;/
ÿ
5A
ÿ
Y4
3;12;R
ÿ
X<4
2ÿ
?
4
3;12;ÿ
4
2ÿ
8;/
2510?
ÿ
.
5ÿ
=5>ÿ
01:ÿ
@0=ÿ
15.
ÿ
C;ÿ
2>C?
4
3;12;:6
0224
H1;:6
ÿ
5/
ÿ
.
/
012A
;/
/
;:ÿ
C=ÿ
=5>ÿ
.
5ÿ
01=ÿ
5.
<;/
ÿ
8;/
251ÿ
O4
.
<5>.
ÿ
8>C?
4
2<;/
F
2ÿ
O/
4
.
.
;1ÿ
8;/
@4
224
51J
SZJ
ÿ
W5ÿ
[@;1:@;1.
ÿ
\]3;8.
ÿ
4
1ÿ
Q/
4
.
4
1HR
ÿ
X<4
2ÿ
?
4
3;12;ÿ
@0=ÿ
15.
ÿ
C;ÿ
0@;1:;:ÿ
;]3;8.
ÿ
4
1ÿ
0ÿ
O/
4
.
4
1H
24
H1;:ÿ
C=ÿ
C5.
<ÿ
80/
.
4
;2ÿ
B
5/
6
ÿ
4
1ÿ
.
<;ÿ
302;ÿ
5A
ÿ
8>C?
4
2<;/
6
ÿ
C=ÿ
DDDÿ
51ÿ
8>C?
4
2<;/
F
2ÿ
C;<0?
A
E
J
S^J
ÿ
_C`
;3.
4
51ÿ
.
5ÿ
D51.
/
0/
=ÿ
X;/
@2R
ÿ
I>C?
4
2<;/
ÿ
<;/
;C=ÿ
5C`
;3.
2ÿ
.
5ÿ
01=ÿ
.
;/
@2ÿ
351.
04
1;:ÿ
4
1ÿ
01=
8>/
3<02;ÿ
5/
:;/
6
ÿ
03L15O?
;:H@;1.
6
ÿ
3<;3Lÿ
;1:5/
2;@;1.
ÿ
5/
ÿ
5.
<;/
ÿ
O/
4
.
4
1Hÿ
8/
;80/
;:ÿ
C=ÿ
=5>6
O<4
3<ÿ
.
;/
@2ÿ
0/
;ÿ
4
135124
2.
;1.
ÿ
O4
.
<ÿ
.
<;2;ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
512ÿ
5/
ÿ
DDDF
2ÿ
G4
?
?
4
1Hÿ
01:ÿ
I0=@;1.
.
;/
@2ÿ
01:ÿ
351:4
.
4
512J
ÿ
ÿ
X<;2;ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
5126
ÿ
.
5H;.
<;/
ÿ
O4
.
<ÿ
DDDF
2ÿ
G4
?
?
4
1Hÿ
01:ÿ
I0=@;1.
.
;/
@2ÿ
01:ÿ
351:4
.
4
512ÿ
B
O<4
3<ÿ
0/
;ÿ
4
135/
85/
0.
;:ÿ
<;/
;4
1E
6
ÿ
35@8/
4
2;ÿ
.
<;ÿ
;1.
4
/
;ÿ
0H/
;;@;1.
C;.
O;;1ÿ
=5>ÿ
01:ÿ
8>C?
4
2<;/
ÿ
B
01:ÿ
DDDE
ÿ
3513;/
14
1Hÿ
.
<4
2ÿ
?
4
3;124
1Hÿ
.
/
01203.
4
51J
ÿ
ÿ
K
1ÿ
.
<;ÿ
;9;1.
ÿ
5A
01=ÿ
351A
?
4
3.
ÿ
C;.
O;;1ÿ
=5>/
ÿ
5C?
4
H0.
4
512ÿ
;2.
0C?
4
2<;:ÿ
C=ÿ
.
<;2;ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
512ÿ
01:ÿ
.
<52;
;2.
0C?
4
2<;:ÿ
C=ÿ
DDDF
2ÿ
G4
?
?
4
1Hÿ
01:ÿ
I0=@;1.
ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
5126
ÿ
.
<;2;ÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
512
2<0?
?
ÿ
351.
/
5?
J
SaJ
ÿ
b;9530.
4
51R
ÿ
\?
2;94
;/
ÿ
5/
ÿ
D58=/
4
H<.
ÿ
D?
;0/
013;ÿ
D;1.
;/
ÿ
@0=ÿ
:;1=ÿ
.
<;ÿ
8;/
@4
224
512ÿ
:;23/
4
C;:
4
1ÿ
.
<4
2ÿ
Y4
3;12;ÿ
0.
ÿ
.
<;4
/
ÿ
25?
;ÿ
:4
23/
;.
4
516
ÿ
A
5/
ÿ
01=ÿ
/
;0251ÿ
5/
ÿ
15ÿ
/
;02516
ÿ
O4
.
<ÿ
0ÿ
A
>?
?
ÿ
/
;A
>1:ÿ
80=0C?
;
.
5ÿ
=5>J
ÿ
ÿ
W5.
4
3;ÿ
5A
ÿ
2>3<ÿ
:;14
0?
ÿ
O4
?
?
ÿ
C;ÿ
@0:;ÿ
>24
1Hÿ
.
<;ÿ
351.
03.
ÿ
4
1A
5/
@0.
4
51ÿ
8/
594
:;:ÿ
C=ÿ
=5>J
ÿ
M04
?
>/
;ÿ
.
5ÿ
/
;3;4
9;ÿ
2>3<ÿ
15.
4
3;ÿ
O4
?
?
ÿ
15.
ÿ
0?
.
;/
ÿ
5/
ÿ
4
190?
4
:0.
;ÿ
.
<;ÿ
:;14
0?
J
ÿ
ÿ
K
1ÿ
15ÿ
;9;1.
ÿ
O4
?
?
ÿ
\?
2;94
;/
5/
ÿ
D58=/
4
H<.
ÿ
D?
;0/
013;ÿ
D;1.
;/
ÿ
C;ÿ
/
;285124
C?
;ÿ
5/
ÿ
?
4
0C?
;ÿ
A
5/
ÿ
01=ÿ
352.
26
ÿ
;]8;12;2ÿ
5/
ÿ
:0@0H;
4
13>/
/
;:ÿ
C=ÿ
=5>ÿ
02ÿ
0ÿ
/
;2>?
.
ÿ
5A
ÿ
0ÿ
:;14
0?
ÿ
5A
ÿ
=5>/
ÿ
8;/
@4
224
51ÿ
/
;c>;2.
6
ÿ
5.
<;/
ÿ
.
<01ÿ
0ÿ
/
;A
>1:ÿ
5A
ÿ
.
<;
0@5>1.
B
2E
ÿ
804
:ÿ
C=ÿ
=5>ÿ
.
5ÿ
\?
2;94
;/
ÿ
01:d
5/
ÿ
D58=/
4
H<.
ÿ
D?
;0/
013;ÿ
D;1.
;/
ÿ
A
5/
ÿ
:;14
;:
8;/
@4
224
512J
efgfhijÿ
eflimni
X<;ÿ
A
5?
?
5O4
1Hÿ
.
;/
@2ÿ
01:ÿ
351:4
.
4
512ÿ
088?
=ÿ
51?
=ÿ
.
5ÿ
28;34
A
4
3ÿ
?
4
3;12;ÿ
.
=8;2R
SoJ
ÿ
hpqrst
qu
v
wrR
ÿ
X<4
2ÿ
8;/
@4
224
51ÿ
4
2ÿ
H/
01.
;:ÿ
A
5/
ÿ
151x
;]3?
>24
9;ÿ
O5/
?
:ÿ
iryt
v
szÿ
/
4
H<.
2ÿ
51?
=
>1?
;22ÿ
=5>/
ÿ
?
4
3;12;ÿ
O02ÿ
H/
01.
;:ÿ
A
5/
ÿ
.
/
012?
0.
4
51ÿ
/
4
H<.
2J
ÿ
K
A
ÿ
=5>ÿ
?
4
3;12;:ÿ
.
/
012?
0.
4
51ÿ
/
4
H<.
2ÿ
=5>
@0=ÿ
51?
=ÿ
.
/
012?
0.
;ÿ
.
<4
2ÿ
351.
;1.
ÿ
4
1.
5ÿ
.
<;ÿ
?
01H>0H;2ÿ
=5>ÿ
/
;c>;2.
;:J
ÿ
[ÿ
8/
5A
;224
510?
ÿ
.
/
012?
0.
5/
@>2.
ÿ
8;/
A
5/
@ÿ
0?
?
ÿ
.
/
012?
0.
4
512ÿ
01:ÿ
/
;8/
5:>3;ÿ
.
<;ÿ
351.
;1.
ÿ
O5/
:ÿ
A
5/
ÿ
O5/
:ÿ
8/
;2;/
94
1Hÿ
.
<;
4
1.
;H/
4
.
=ÿ
5A
ÿ
.
<;ÿ
0/
.
4
3?
;J
0123423131 56789 6 ÿ6 9ÿÿ6 9
89922011 6789 2 9 ! 6 26 9"!#$% & ! 6 '!()&*10+1,-10 .2,
